Tarcocimab tedromer (KSI-501) - (DAYBREAK)

September 25, 2026: Kodiak Sciences (NASDAQ: KOD) said it will report topline results on September 28, 2026 from DAYBREAK, a Phase 3 study evaluating Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) in patients with wet age-related macular degeneration. The company will host a webcast at 8:30 a.m. Eastern Time that day.

The release does not disclose efficacy or safety results; the catalyst is the imminent Phase 3 topline readout.

Other upcoming catalysts mentioned: KSI-101, a bispecific protein in two Phase 3 studies in macular edema secondary to inflammation, has topline data expected for Pivotal Analysis 1 (PEAK) in December 2026 and for Pivotal Analysis 2 (PEAK+PINNACLE) in 2Q 2027. The company also says Zenkuda has a “BLA-ready profile” in diabetic retinopathy, retinal vein occlusion, and wet AMD, and that KSI-501 is also being evaluated in diabetic macular edema.